|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 320.66 USD | +0.05% |
|
-3.19% | -19.36% |
| 03-05 | Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement | CI |
| 03-05 | Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments | RE |
| Capitalization | 42.51B 36.65B 33.08B 31.74B 57.89B 3,906B 60.58B 391B 157B 1,873B 160B 156B 6,700B | P/E ratio 2026 * |
47.8x | P/E ratio 2027 * | 29.5x |
|---|---|---|---|---|---|
| Enterprise value | 39.11B 33.72B 30.44B 29.21B 53.26B 3,594B 55.74B 360B 144B 1,724B 147B 144B 6,165B | EV / Sales 2026 * |
7.01x | EV / Sales 2027 * | 4.93x |
| Free-Float |
99.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | +0.05% | ||
| 1 week | -3.19% | ||
| Current month | -3.68% | ||
| 1 month | -3.19% | ||
| 3 months | -30.01% | ||
| 6 months | -29.06% | ||
| Current year | -19.36% |
| 1 week | 312.09 |  | 334.42 |
| 1 month | 298 | | 345.9 |
| Current year | 298 | | 427.05 |
| 1 year | 205.87 | | 495.55 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/2021 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 12/08/2019 |
| Chief Tech/Sci/R&D Officer | - | 31/03/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 22/04/2012 |
Amy Schulman
CHM | Chairman | 65 | 04/01/2023 |
David Pyott
BRD | Director/Board Member | 72 | 17/12/2015 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 5.08% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.05% | -3.19% | +28.66% | +58.29% | 42.51B | |
| +0.72% | -3.10% | +6.52% | +211.00% | 878B | |
| +0.32% | -1.26% | +45.59% | +56.08% | 577B | |
| -0.96% | +2.41% | +8.78% | +47.45% | 411B | |
| -2.93% | -6.16% | +12.53% | +24.59% | 359B | |
| -1.85% | -4.04% | +20.21% | +34.46% | 305B | |
| -1.25% | -3.78% | +23.26% | +55.34% | 304B | |
| -0.24% | -2.94% | +24.25% | +8.34% | 287B | |
| +0.53% | -2.58% | +16.73% | +57.37% | 198B | |
| -0.83% | +0.11% | +24.68% | +77.54% | 180B | |
| Average | -0.63% | -1.33% | +21.12% | +63.05% | 354.2B | |
| Weighted average by Cap. | -0.60% | -1.63% | +19.57% | +85.71% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.58B 4.81B 4.34B 4.17B 7.6B 513B 7.95B 51.35B 20.57B 246B 20.95B 20.5B 880B | 7.28B 6.28B 5.67B 5.44B 9.92B 669B 10.38B 67B 26.84B 321B 27.33B 26.75B 1,148B |
| Net income | 943M 813M 734M 704M 1.28B 86.62B 1.34B 8.67B 3.47B 41.54B 3.54B 3.46B 149B | 1.52B 1.31B 1.19B 1.14B 2.07B 140B 2.17B 14.01B 5.61B 67.11B 5.72B 5.59B 240B |
| Net Debt | -3.39B -2.93B -2.64B -2.53B -4.62B -312B -4.84B -31.23B -12.51B -150B -12.74B -12.47B -535B | -6.61B -5.7B -5.15B -4.94B -9B -608B -9.42B -60.83B -24.37B -291B -24.81B -24.28B -1,042B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/03/26 | 320.66 $ | +0.05% | 983,183 |
| 05/03/26 | 320.51 $ | -2.07% | 1,215,172 |
| 04/03/26 | 327.30 $ | +2.71% | 931,151 |
| 03/03/26 | 318.65 $ | -1.97% | 947,625 |
| 02/03/26 | 325.07 $ | -2.36% | 1,302,332 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition